← Back to Screener
ANI Pharmaceuticals, Inc. (ANIP)
Price$78.07
Favorite Metrics
Price vs S&P 500 (26W)-20.54%
Price vs S&P 500 (4W)-2.71%
Market Capitalization$1.72B
P/E Ratio (Annual)22.01x
All Metrics
P/CF (Annual)9.31x
Book Value / Share (Quarterly)$24.03
P/TBV (Annual)28.98x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)40.81%
Cash Flow / Share (Quarterly)$7.62
Payout Ratio (TTM)2.28%
Price vs S&P 500 (YTD)-5.76%
Gross Margin (TTM)61.36%
Net Profit Margin (TTM)8.87%
EPS (TTM)$3.70
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$3.70
Revenue Growth (5Y)33.48%
EPS (Annual)$3.69
Dividend / Share (Annual)$0.05
ROI (Annual)6.77%
Gross Margin (Annual)61.36%
Net Profit Margin (5Y Avg)-5.03%
Cash / Share (Quarterly)$13.10
P/E Basic Excl Extra (TTM)22.01x
Revenue Growth QoQ (YoY)29.64%
P/E Normalized (Annual)22.01x
ROA (Last FY)5.44%
Revenue Growth TTM (YoY)43.78%
EBITD / Share (TTM)$9.78
ROE (5Y Avg)-2.35%
Operating Margin (TTM)12.58%
Cash Flow / Share (Annual)$7.62
P/B Ratio3.19x
P/B Ratio (Quarterly)3.28x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.33x
Net Interest Coverage (TTM)6.56x
ROA (TTM)5.71%
EV / EBITDA (TTM)10.05x
EPS Incl Extra (Annual)$3.69
Current Ratio (Annual)2.71x
Quick Ratio (Quarterly)2.07x
3-Month Avg Trading Volume0.42M
52-Week Price Return11.29%
EV / Free Cash Flow (Annual)11.99x
P/E Incl Extra (TTM)22.01x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.72
P/S Ratio (Annual)1.95x
Asset Turnover (Annual)0.61x
52-Week High$99.50
Operating Margin (5Y Avg)-1.69%
EPS Excl Extra (Annual)$3.69
CapEx CAGR (5Y)17.64%
Tangible BV CAGR (5Y)13.56%
26-Week Price Return-16.55%
Quick Ratio (Annual)2.07x
13-Week Price Return-9.33%
Total Debt / Equity (Annual)1.14x
Current Ratio (Quarterly)2.71x
Enterprise Value$2,055.482
Revenue / Share Growth (5Y)19.09%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)8.77%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.44x
Pretax Margin (Annual)10.84%
Cash / Share (Annual)$13.10
3-Month Return Std Dev37.82%
Gross Margin (5Y Avg)58.58%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)48.72%
EBITDA Interim CAGR (5Y)39.30%
ROE (Last FY)14.49%
Net Interest Coverage (Annual)6.56x
EPS Basic Excl Extra (Annual)$3.69
P/FCF (TTM)10.06x
Receivables Turnover (TTM)3.51x
EV / Free Cash Flow (TTM)11.99x
Total Debt / Equity (Quarterly)1.14x
EPS Incl Extra (TTM)$3.70
Receivables Turnover (Annual)3.51x
ROI (TTM)7.07%
P/S Ratio (TTM)1.95x
Pretax Margin (5Y Avg)-6.90%
Revenue / Share (Annual)$41.61
Tangible BV / Share (Annual)$2.72
Forward P/E8.60x
Free OCF CAGR (5Y)79.76%
Price vs S&P 500 (52W)-18.54%
P/E Ratio (TTM)22.01x
EPS Growth TTM (YoY)237.36%
Year-to-Date Return-3.12%
5-Day Price Return-4.57%
EPS Normalized (Annual)$3.69
ROA (5Y Avg)-1.15%
Net Profit Margin (Annual)8.87%
Month-to-Date Return-0.55%
Cash Flow / Share (TTM)$4.03
EBITD / Share (Annual)$9.63
Operating Margin (Annual)12.58%
LT Debt / Equity (Annual)1.11x
P/CF (TTM)9.31x
ROI (5Y Avg)-1.34%
P/E Excl Extra (TTM)22.01x
LT Debt / Equity (Quarterly)1.11x
EPS Basic Excl Extra (TTM)$3.70
P/TBV (Quarterly)28.98x
Payout Ratio (Annual)1.48%
P/B Ratio (Annual)3.28x
Dividend / Share (TTM)$0.05
Inventory Turnover (TTM)2.44x
Pretax Margin (TTM)10.84%
Book Value / Share (Annual)$24.03
Price vs S&P 500 (13W)-10.02%
Dividend Yield (TTM)0.07%
Beta0.46x
P/FCF (Annual)10.06x
Revenue / Share (TTM)$39.83
ROE (TTM)16.06%
52-Week Low$56.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANIPANI Pharmaceuticals, Inc. | 1.95x | 43.78% | 61.36% | — | $78.07 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
ANI Pharmaceuticals manufactures and markets generic prescription medications, specializing in narcotics, hormones, steroids, and complex formulations including extended-release and combination products. The company operates two business segments—Rare Diseases and Brands, Generics, and Others—with primary operations in the United States and a smaller Canadian presence.